Frazier Life Sciences Management, L.P. Erasca, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $1.7 Billion
- Q2 2024
A detailed history of Frazier Life Sciences Management, L.P. transactions in Erasca, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 16,216,216 shares of ERAS stock, worth $48 Million. This represents 2.26% of its overall portfolio holdings.
Number of Shares
16,216,216Holding current value
$48 Million% of portfolio
2.26%Shares
1 transactions
Others Institutions Holding ERAS
# of Institutions
133Shares Held
205MCall Options Held
3.1KPut Options Held
142K-
Vr Adviser, LLC New York, NY16.2MShares$48 Million4.2% of portfolio
-
Suvretta Capital Management, LLC New York, NY13.8MShares$40.8 Million1.36% of portfolio
-
Arch Venture Management, LLC Chicago, IL11.1MShares$32.7 Million15.29% of portfolio
-
Black Rock Inc. New York, NY10.6MShares$31.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.4MShares$30.6 Million0.0% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $362M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...